Edwards focuses on peripheral stent development
This article was originally published in Clinica
Edwards Lifesciences has formed two deals aimed at strengthening its position in treatments for peripheral vascular disease. Under the first deal, it has gained non-coronary stent technologies from private company Orbus Medical Technologies through an exclusive licensing agreement. The second is a related product development agreement with private company Syntheon.
You may also be interested in...
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.